ReachMD

Be part of the knowledge.™

Rare and Orphan Diseases

142

LikeLikedUnlike

Episodes 1-15 of 33

- Frederic Rahbari-Oskoui, MD, MSc
  Peer
1
CME/CE
Case Management Strategies for Patients with ADPKD – Part 2
Case Management Strategies for Patients with ADPKD – Part 2
0.50 credits
- Martin Pollak, MD
  Peer
- Susanne Nicholas, MD, MPH, PhD
  Peer
2
CME/CE
Talking Rare: Epidemiology and Pathogenesis of APOL1-Mediated Kidney Disease
Talking Rare: Epidemiology and Pathogenesis of APOL1-Mediated Kidney Disease
0.25 credits
- Kristen Nowak, PhD
  Peer
0
Advances in Chronic Kidney Disease
Interview with the Investigator
Interview with the Investigator
0
Advances in Chronic Kidney Disease
A Patient's Journey with ADPKD
A Patient's Journey with ADPKD
- Maria Fleseriu, MD, FACE
  Peer
- Irina Bancos, MD
  Peer
2
CME/CE
Personalizing Treatment in Cushing’s Disease
Personalizing Treatment in Cushing’s Disease
0.25 credits
- Cem Akin, MD, PhD
  Peer
- Jason Gotlib, MD, MS
  Peer
6
CME/CE
Indolent Systemic Mastocytosis (ISM): Tools to Diagnose ISM
Indolent Systemic Mastocytosis (ISM): Tools to Diagnose ISM
0.25 credits
- Rami Komrokji, MD
  Peer
- Michael R. Savona, MD
  Peer
- Jamile Shammo, MD, FASCP, FACP
  Peer
6
CME/CE
Shifting Paradigms for Assessment and Management of Lower-Risk Myelodysplastic Syndromes: Genomics, Risk Stratification, and Novel Therapies
Shifting Paradigms for Assessment and Management of Lower-Risk Myelodysplastic Syndromes: Genomics, Risk Stratification, and Novel Therapies
1.00 credits
- Caitlin Costello, MD
  Peer
3
Oncology and Hematology
Patients as Partners in Multiple Myeloma: What to Ask and What to Expect
Patients as Partners in Multiple Myeloma: What to Ask and What to Expect
- Amrita Krishnan, MD
  Peer
- Morie Gertz, MD, MACP
  Peer
3
CME/CE
Keeping Pace in Hematologic Malignancies: Optimizing Treatment Selection in Relapsed or Refractory Multiple Myeloma
Keeping Pace in Hematologic Malignancies: Optimizing Treatment Selection in Relapsed or Refractory Multiple Myeloma
0.25 credits
- Caitlin Costello, MD
  Peer
- Ravi Vij, MD
  Peer
6
CME/CE
Patients as Partners: Frontline Management of Multiple Myeloma
Patients as Partners: Frontline Management of Multiple Myeloma
0.25 credits
- Cesar Rodriquez Valdes, MD
  Peer
- Amrita Krishnan, MD
  Peer
5
CME/CE
Keeping Pace in Hematologic Malignancies: Novel Targets for Multiple Myeloma
Keeping Pace in Hematologic Malignancies: Novel Targets for Multiple Myeloma
0.25 credits
- Monique Hartley-Brown, MD, MMSc
  Peer
- Shonali Midha, MD
  Peer
3
CME/CE
Keeping Pace in Hematologic Malignancies: Newly Diagnosed Multiple Myeloma
Keeping Pace in Hematologic Malignancies: Newly Diagnosed Multiple Myeloma
0.25 credits
- Shaji K. Kumar, MD
  Peer
- María-Victoria Mateos, MD, PhD
  Peer
3
CME/CE
Keeping Pace in Hematologic Malignancies: Updates from ASCO 2022
Keeping Pace in Hematologic Malignancies: Updates from ASCO 2022
0.25 credits
- Sagar Lonial, MD, FACP
  Peer
- Noopur Raje, MD
  Peer
3
CME/CE
Novel Clinical Approaches in Multiple Myeloma: CAR T Cell Therapy
Novel Clinical Approaches in Multiple Myeloma: CAR T Cell Therapy
0.25 credits
- Anthony Mato, MD, MSCE
  Peer
3
CME/CE
Non-Covalent BTK Inhibitors for B-Cell Malignancies (MCL/CLL): Setting the Stage for Future Use
Non-Covalent BTK Inhibitors for B-Cell Malignancies (MCL/CLL): Setting the Stage for Future Use
0.50 credits

Program Chapters

Segment Chapters

Playlist:

Recommended